Enhancer of zeste homolog 2 (EZH2) is a catalytic subunit of the Polycomb-repressive complex 2 (PRC2), which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 (H3K27me3).
Xia & He Publishing Inc.Aug 9 2024 Enhancer of zeste homolog 2 is a catalytic subunit of the Polycomb-repressive complex 2 , which plays a crucial role in transcriptional repression through the methylation of histone H3 on lysine 27 . This epigenetic modification leads to chromatin compaction and gene silencing . EZH2 is frequently overexpressed in a variety of cancers, including head and neck, breast, prostate, bladder, colorectal, lung, pancreatic, melanoma, and lymphoma.
EZH2 and the tumor microenvironment Recent studies have highlighted the pleiotropic effects of EZH2 on both tumor and immune cells. EZH2 modulates the tumor immune microenvironment by affecting the function of various immune cells, including T cells, dendritic cells, and macrophages. This modulation can either promote or inhibit tumor growth, depending on the context.
Combining EZH2 inhibitors with immunotherapy Combining EZH2 inhibitors with immunotherapies has shown synergistic effects in preclinical models. For instance, the combination of EZH2 inhibitors with PD-1 blockers has demonstrated increased macrophage toxicity and enhanced immunotherapy efficacy in malignant pleural mesothelioma.
Cancer Immunotherapy Immunotherapy Bladder Cell Chromatin Colorectal Efficacy Gene Gene Silencing Glycolysis Lymphoma Lysine Melanoma Neck Oncogene PD-L1 Preclinical Prostate Protein Research Sarcoma Tumor
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Overcoming cancer relapse with CAR-Enhancer therapyEven as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse.
Read more »
Overcoming cancer relapse with CAR-Enhancer therapyEven as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse.
Read more »
Targeting oncogenic transcription factors to develop potential new cancer treatmentsA new study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.
Read more »
New findings on possible therapies to target oncogenic transcription factors in multiple cancer typesA new study from the University of Michigan Health Rogel Cancer Center furthers research that suggests the potential of developing new cancer treatments to target oncogenic transcription factors by indirectly affecting their ability to access enhancer DNA in chromatin.
Read more »
One in 10 women in the UK with common but ‘debilitating’ condition are at ‘increased risk’ of ovarian cance...What is Endometriosis
Read more »
Review of fasting-mimicking diets in cancer treatmentResearchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.
Read more »